Pear Therapeutics Reports Net Loss of $75.5 Million in 2022

Pear Therapeutics, Inc.(PEARQ) releases its 2022 financial results, showcasing a significant increase in revenue but also reporting a net loss for the year.Pear Therapeutics, a leading digital therapeutics company, has published its consolidated financial statements for the year ended December 31, 2022. The report reveals both positive and challenging outcomes for the company, with a substantial surge in revenue and the acknowledgment of a net loss. Pear Therapeutics' innovative approach to healthcare has continued to gain traction, evident in its impressive revenue growth.

Revenue Soars to $12.7 Million

In 2022, Pear Therapeutics experienced a remarkable increase in revenue, reaching $12.7 million. This surge reflects the company's successful product revenue, collaboration and license revenue, as well as subscription, support, and professional services revenue. Comparatively, the previous year's revenue stood at $4.2 million, indicating a significant year-over-year growth of approximately 202%.

Net Loss of $75.5 Million